QuidelOrtho Corporation QDEL
Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
QuidelOrtho Corporation is a U.S.-based diagnostics company focused on developing, manufacturing, and commercializing diagnostic testing technologies used in hospitals, clinical laboratories, physician offices, retail settings, and point-of-care environments. The company operates within the in vitro diagnostics industry and serves healthcare providers, laboratories, public health agencies, and blood and plasma screening organizations. QuidelOrtho was formed through the combination of Quidel Corporation and Ortho Clinical Diagnostics, creating a broader diagnostics platform spanning rapid diagnostics, immunohematology, clinical chemistry, molecular diagnostics, and transfusion medicine.
The company’s primary revenue drivers include its Labs, Transfusion Medicine, and Point of Care business segments, with recurring revenue generated from consumables, reagents, testing cartridges, and instrument placements. QuidelOrtho maintains a competitive position through its installed instrument base, long-standing hospital and laboratory relationships, and broad menu of diagnostic assays. Historically, Quidel expanded through rapid infectious disease testing and molecular diagnostics, while Ortho Clinical Diagnostics contributed a large global laboratory diagnostics franchise and transfusion medicine business. The merger materially expanded the company’s international scale and product breadth.
Business Operations
QuidelOrtho organizes operations across several major diagnostic platforms, including Labs, Transfusion Medicine, and Point of Care. The Labs segment includes clinical chemistry, immunodiagnostics, and automation systems used by hospital and reference laboratories. The Transfusion Medicine segment focuses on blood typing, donor screening, and transfusion compatibility testing products. The Point of Care segment includes rapid antigen and molecular tests for infectious diseases such as influenza, COVID-19, RSV, and strep infections. Revenue is generated through sales of instruments, consumables, reagents, testing kits, service agreements, and recurring laboratory supply contracts.
The company operates globally through manufacturing facilities, commercial operations, and distribution networks across North America, Europe, Asia-Pacific, Latin America, and the Middle East. QuidelOrtho controls a range of proprietary diagnostic technologies, including immunoassay systems, molecular amplification platforms, blood typing systems, and clinical chemistry analyzers. Key operational assets include the Vitros laboratory systems franchise and the Sofia rapid diagnostics platform. The company also maintains partnerships with healthcare systems, distributors, and laboratory networks to support product deployment and service coverage internationally.
Strategic Position & Investments
QuidelOrtho’s strategic direction has focused on expanding recurring revenue streams, increasing automation in laboratory diagnostics, and strengthening its position in decentralized and point-of-care testing. Following the merger between Quidel and Ortho Clinical Diagnostics, the company emphasized operational integration, portfolio cross-selling, and global commercial expansion. Management has also prioritized margin improvement, manufacturing optimization, and debt reduction associated with the merger transaction.
The company has invested in molecular diagnostics, respiratory disease testing, immunohematology automation, and high-throughput laboratory platforms. Strategic acquisitions have included Ortho Clinical Diagnostics, which significantly increased Quidel’s global scale and diversified its revenue base beyond rapid diagnostics. QuidelOrtho continues to participate in emerging diagnostic areas including syndromic respiratory testing, automation-enabled laboratory workflows, and digital connectivity solutions tied to diagnostic instrumentation. Public filings and company disclosures indicate ongoing investment in assay menu expansion and installed instrument growth.
Geographic Footprint
QuidelOrtho is headquartered in San Diego, California, with substantial operational and commercial activities in the United States, Europe, Asia-Pacific, Latin America, and the Middle East & Africa. The company maintains a broad international footprint through direct sales organizations, distributor relationships, manufacturing facilities, and laboratory support operations. A significant portion of revenue is generated outside the United States, reflecting the legacy global infrastructure of Ortho Clinical Diagnostics.
The company serves customers in more than 100 countries, with particularly strong positions in hospital laboratories and transfusion medicine markets across North America and Europe. International operations include manufacturing, research and development, logistics, and technical support functions. QuidelOrtho’s global installed instrument base and long-term laboratory customer relationships provide recurring consumables revenue and support continued expansion into emerging healthcare markets.
Leadership & Governance
QuidelOrtho’s leadership team combines executives with backgrounds in diagnostics, medical technology, laboratory services, and healthcare operations. Following the merger that created the company, management focused on integrating legacy Quidel and Ortho Clinical Diagnostics operations while maintaining investment in innovation and commercial expansion. Leadership has emphasized operational efficiency, customer retention, scientific innovation, and strengthening recurring revenue through installed diagnostic systems.
Key executives include:
- Brian J. Blaser – President and Chief Executive Officer
- Joseph M. Busky – Chief Financial Officer
- Jonathan R. Siegel – Executive Chairman
- Michael P. Murphy – President, North America
- Amanda Maxwell – Chief Human Resources Officer
- Kathleen Orland – Chief Legal Officer and Corporate Secretary
The company operates under a publicly traded corporate governance framework and files regular disclosures through SEC filings, including annual and quarterly reports. Governance oversight is conducted through the board of directors and its committees, with strategic priorities centered on diagnostics innovation, operational integration, and global market expansion.